Compared with placebo, the drug tafamidis (Pfizer) reduces decline in left ventricular (LV) systolic and diastolic function, suggests post hoc analysis of a randomized trial of patients with ...
Cardiac transthyretin amyloidosis (also called ATTR amyloidosis cardiomyopathy or ATTR-CM) is a progressive disease and a cause of fatal heart failure resulting from extracellular myocardial ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...
According to new research, patisiran maintains long-term kidney function in ATTR-PN. Long-term patisiran treatment maintained stable eGFR in patients with ATTR-PN and chronic kidney disease, ...
Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly the ...
Please provide your email address to receive an email when new articles are posted on . Alnylam announced positive top-line results of its phase 3 trial of vutrisiran for the treatment of ATTR ...
− Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to Placebo – “The HELIOS-B study continues to deliver a robust data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback